RAF1 and neoplasm: Multitargeted tyrosine kinase inhibitors (TKIs), such as sorafenib, can suppress tumor cell proliferation by inhibiting Raf-1, B-Raf, and kinase activity in the Ras/Raf/MEK/ERK signaling pathway.